Sputnik V Is Great Vaccine, Will Save Lots of Lives: RDIF CEO

The transcript discusses the distribution of the Sputnik V vaccine in Latin America, focusing on Venezuela and Argentina. It covers the manufacturing and supply chain, highlighting partnerships in Brazil, India, Korea, and China. The conversation addresses public perception and demand for the vaccine in Russia, countering negative narratives. It also mentions the publication of peer-reviewed data and collaborations with other vaccine manufacturers, emphasizing the vaccine's safety and efficacy.

What is the expected timeline for delivering Sputnik V doses to Venezuela?

• Starting in January

• By the end of February

• By the end of December

• In March

Which countries are involved in the manufacturing partnerships for Sputnik V?

• South Africa, Egypt, Turkey, and Saudi Arabia

• Canada, Mexico, Japan, and Australia

• Germany, France, Italy, and Spain

• Brazil, India, Korea, and China

What percentage of Russians, according to the survey mentioned, are willing to get vaccinated with Sputnik V?

• 42%

• 38%

• 50%

• 60%

What is the main reason for the skepticism towards the Sputnik V vaccine in Russia?

• Limited availability in Russia

• High cost of the vaccine

• Negative narratives from Western media

• Lack of peer-reviewed data

What is one of the advantages of the Sputnik V vaccine mentioned in the transcript?

• It can be stored at plus 2 to 8 degrees

• It is more expensive than other vaccines

• It uses a single vector for delivery

• It requires storage at minus 70 degrees

Which magazine published the phase one and two data of the Sputnik V vaccine?

• The Lancet

• Nature

• Science

• New England Journal of Medicine

What is the expected outcome of the collaboration between Sputnik V and AstraZeneca?

• A new vaccine requiring three doses

• A vaccine that is less effective

• A combination that enhances AstraZeneca's vaccine

• A vaccine that needs minus 70 degrees storage